Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial results

AstraZeneca tozorakimab Phase III COPD success

Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026

Sentiment
70
Attention
6
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The positive results position tozorakimab as a potential best-in-class COPD treatment, expanding AstraZeneca's respiratory franchise and likely boosting its revenue outlook. The FDA Priority Review acceptance accelerates potential market entry, positively impacting AstraZeneca's stock and the broader respiratory biologics market.

Pharmaceuticals Biotechnology

AstraZeneca announced positive full results from the Phase III OBERON and TITANIA trials of tozorakimab, a first-in-class IL-33-targeting monoclonal antibody, in chronic obstructive pulmonary disease (COPD). Tozorakimab 300mg every four weeks reduced moderate and severe exacerbations by 29-34% in former smokers and 29-30% in the overall population versus placebo, on top of inhaled standard of care. It was the first biologic to show efficacy across all blood eosinophil counts and smoking statuses, and also reduced mucus plugging. The data were presented at the European Respiratory Society Congress and published in the The New England Journal of Medicine. The United States — Food and Drug Administration accepted the Biologics License Application for Priority Review, with a PDUFA date expected in Q1 2027. Tozorakimab is also under regulatory review in the European Union and China, and is being studied in asthma and severe viral lower respiratory tract disease.

100 AstraZeneca reported positive results
stock
Developer of tozorakimab; positive trial results and FDA Priority Review acceptance strengthen its COPD pipeline and commercial prospects.
Importance 100.0 Sentiment 80.0
govactor
Regulatory body that accepted the BLA for Priority Review, setting a PDUFA date in Q1 2027; decision will determine US market access.
Importance 60.0 Sentiment 0.0
cnt
Regulatory jurisdiction where tozorakimab is under review for COPD; approval would expand market access.
Importance 30.0 Sentiment 0.0
ngo
Venue for late-breaking presentation of the trial results at its 2026 Congress.
Importance 30.0 Sentiment 0.0
alliance
Regulatory jurisdiction where tozorakimab is under review for COPD; approval would expand market access.
Importance 30.0 Sentiment 0.0
per
AstraZeneca executive who publicly endorsed the results; her statements reflect company confidence.
Importance 20.0 Sentiment 0.0
per
Chief investigator of the LUNA programme who provided expert commentary on the clinical significance.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.